Related Experiment Videos
[Invasive aspergillosis: treatment]
P Saballs-Radresa1, J L López-Colomés, J Gimeno-Cobos
1Hospital del Mar, Passeig Marítim 25-29, 08003 Barcelona, España. 12822@imas.imim.es
Revista Iberoamericana De Micologia
|March 15, 2005
Summary
Invasive aspergillosis is a serious fungal infection primarily impacting immunocompromised patients. Early diagnosis and prompt treatment with available or emerging antifungal therapies, alongside potential surgical intervention, are crucial for patient outcomes.
Area of Science:
- Mycology
- Infectious Diseases
- Clinical Pharmacology
Context:
- Invasive aspergillosis poses a significant threat to immunocompromised individuals, including those with congenital or acquired immunodeficiencies, neutropenia, organ transplants, or undergoing chemotherapy and corticosteroid therapy.
- Current treatment options for invasive aspergillosis are limited, necessitating a thorough understanding of available antifungals.
Purpose:
- To provide a comprehensive overview of current and emerging therapeutic strategies for invasive aspergillosis.
- To emphasize the importance of understanding patient-specific factors, drug pharmacokinetics, and evidence-based treatment criteria.
Summary:
- The review details existing treatments such as amphotericin B deoxycholate, lipid formulations, and itraconazole, and anticipates the future roles of voriconazole, posaconazole, liposomal nystatin, and echinocandins.
- It highlights the critical need for high clinical suspicion, rapid initiation of antifungal therapy, and consideration of adjuvant treatments, including surgery for specific manifestations like pulmonary aspergillosis and sinusitis.
Impact:
- This information is vital for clinicians managing invasive aspergillosis, enabling informed treatment decisions and improved patient management.
- Optimizing antifungal therapy and surgical interventions can lead to better clinical outcomes and reduced mortality in this vulnerable patient population.